[Cytotoxic effect of CPT-11 against human recurrent carcinoma cells primarily cultured on contact-sensitive plates: preliminary report]. 1992

H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002166 Camptothecin An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity. Camptothecine
D003470 Culture Media Any liquid or solid preparation made specifically for the growth, storage, or transport of microorganisms or other types of cells. The variety of media that exist allow for the culturing of specific microorganisms and cell types, such as differential media, selective media, test media, and defined media. Solid media consist of liquid media that have been solidified with an agent such as AGAR or GELATIN. Media, Culture
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077146 Irinotecan A semisynthetic camptothecin derivative that inhibits DNA TOPOISOMERASE I to prevent nucleic acid synthesis during S PHASE. It is used as an antineoplastic agent for the treatment of COLORECTAL NEOPLASMS and PANCREATIC NEOPLASMS. 7-Ethyl-10-hydroxycamptothecin,CPT 11,CPT-11,Camptosar,Camptothecin-11,Irinotecan Hydrochloride,Irrinotecan,NK012 Compound,SN 38,SN 38 11,SN-38,SN-38-11,7 Ethyl 10 hydroxycamptothecin,CPT11,Camptothecin 11,SN3811
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured

Related Publications

H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
June 1995, Anti-cancer drugs,
H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
January 1994, Anticancer research,
H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
December 1992, Nihon Geka Gakkai zasshi,
H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
June 1994, Japanese journal of cancer research : Gann,
H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
January 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
July 1999, Gan to kagaku ryoho. Cancer & chemotherapy,
H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
November 1985, Japanese journal of cancer research : Gann,
H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
November 1991, Nihon Geka Gakkai zasshi,
H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
January 2008, Oncology,
H Matsuoka, and R Abe, and H Ueo, and T Akiyoshi, and M Furusawa, and M Yamamoto, and K Sugimachi
September 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!